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A B S T R A C T
Apheresis with different procedures and devices are used for a variety of indications that
may have different adverse events (AEs). The aim of this study was to clarify the extent
and possible reasons of various side effects based on data from a multinational registry.
The WAA-apheresis registry data focus on adverse events in a total of 50846 proce-
dures in 7142 patients (42% women). AEs were graded as mild, moderate (need for
medication), severe (interruption due to the AE) or death (due to AE).
More AEs occurred during the ﬁrst procedures versus subsequent (8.4 and 5.5%, re-
spectively). AEs were mild in 2.4% (due to access 54%, device 7%, hypotension 15%, tingling
8%), moderate in 3% (tingling 58%, urticaria 15%, hypotension 10%, nausea 3%), and severe
in 0.4% of procedures (syncope/hypotension 32%, urticaria 17%, chills/fever 8%, arrhythmia/
asystole 4.5%, nausea/vomiting 4%).
Hypotension was most common if albumin was used as the replacement ﬂuid, and ur-
ticaria when plasma was used. Arrhythmia occurred to similar extents when using plasma
or albumin as replacement. In 64% of procedures with bronchospasm, plasma was part of
the replacement ﬂuid used.
Severe AEs are rare. Although most reactions are mild and moderate, several side effects
may be critical for the patient. We present side effects in relation to the procedures and
suggest that safety is increased by regular vital sign measurements, cardiac monitoring and
by having emergency equipment nearby.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Therapeutic apheresis has been widely used since 1975
when Lockwood et al. published the survival beneﬁts of
treating patients with Goodpasture syndrome with immu-
nosuppression and apheresis [1]. The procedure used was
a plasmaﬁltration technique for removal of antibodies. Since
then, the number of techniques [2] as well as the indica-
tions [3] has increased.
When the number of patients increased, it was possi-
ble to perform controlled studies in several of the diseases.
Thus, it became possible to clarify the usefulness of the
therapy for various diseases, and to develop guidelines such
as those of the American Society for Apheresis [3–6]. Still,
clarity and local strategies vary. To ensure increased safety
and eﬃcacy, national quality assessment registries were de-
veloped in Canada [7,8], France [9–11], and some other
countries such as Italy [12–14], Sweden [15,16], Korea [17],
the Czech Republic [18] and Germany [19,20]. For a broader
comparison, a rheopheresis registry has been established
[21] as well as a more general apheresis registry on behalf
of the World Apheresis Association [22,23]. Several inter-
national cross sectional surveys have been performed by
Malchesky et al. [24–26].
The Canadian Apheresis Group (CAG) has combined their
registry activities with randomized multicenter studies re-
sulting in an important milestone showing the beneﬁcial
effects using apheresis in the treatment of thrombotic throm-
bocytopenic purpura [27]. Further CAG studies included
investigations about replacement ﬂuids [28,29], plasma ex-
change for immune thrombocytopenic purpura [30], multiple
sclerosis [31] and myeloma cast nephropathy [32].
Since the extent of side effects during apheresis occurs
at a rate of approximately 5% [22], the number of cases with
various adverse events (AEs) of various grades is rather low
even in larger centers. Using data from larger registries
enables a more accurate estimate of AEs, while controlled
studies are important to clarify indications. To be able to
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compare the extent of AEs between centers and methods,
it is also important to use similar criteria.
The aim of this study was to investigate the extent of
various severe side effects that occur during apheresis so
that the risks for the patients and precautions to be taken
can be clariﬁed.
2. Material and methods
The study included all data entered by the apheresis
centers that participated in the WAA apheresis registry
(www.waa-registry.org). The data for procedures were
entered consecutively and prospectively regarding vari-
ables such as type of procedure, type of replacement ﬂuid,
and type and grade of AEs (Table 1, Appendix). When ana-
lyzing data, a total of 50,846 procedures had been registered
for 7,142 patients (57% men 43% women). The median age
was 55 years (range 0–94 years). Data for AEs were missing
in 5.9% of the procedures (n = 2990 of the ﬁrst treat-
ments). Data were also missing for other variables, thereby
reducing the numbers available for analyses for various
reasons. The speciﬁc analysis of apheresis registry AEs data
was approved by the local ethics committee (D number:
2011-113-31M and 2012-311-32M).
The deﬁnition of grades of AEs are given in Table 1. Hy-
potension was deﬁned as a drop in systolic blood pressure
of more than 40 mmHg or below 90 mmHg. Plasma ex-
change (PE) was performed with replacement with of liquid
stored plasma (LSP), fresh frozen plasma (FFP), cryopre-
cipitate poor plasma (CPP), solvent detergent plasma –
Octaplas® and Octaplas LG®, and hydroxyethyl starch (HES).
Statistical analyses were performed using the Student’s
T-test, Mantel–Haenszel chi square test, and for smaller
numbers the Fisher exact test. Correlation analyses were per-
formed with the Spearman test and the Pearson test for
univariate comparison and linear regression analysis. In the
multivariate analysis, the grade of AE was designed as the
dependent factor entering the variables plasma, albumin,
age, gender and calcium intravenously as prophylaxis and
centers in the model. A two-tailed p-value of less than 0.05
was considered as signiﬁcant. SPSS 19 software was used
as well as open access Epi-info 7 (http://wwwn.cdc.gov/
epiinfo).
3. Results
The various main groups of diseases treated by apheresis
are shown in Table 2.
Data regarding an AE was given for 47,856 procedures.
In 2,760 procedures AEs as well as a speciﬁc grading were
reported (Table 3). So far, no death due to the apheresis treat-
ment was reported. In 0.3% of procedures, the patient
suffered from more than one AE (Table 3). The grade of AE
related to the most common groups of diseases treated is
given in Table 4. The three most common groups were those
treated for endocrine and metabolic (hyperlipidemia con-
tributed to the main part of those procedures), neurologic
and malignant diseases (mainly treated by cytapheresis).
3.1. Mild and moderate adverse events
Mild and moderate AEs were mainly due to access prob-
lems, such as the need for reinsertion of a puncture needle
Table 1
Grading of adverse events (AEs) based on patient experience and outcome.
Grading Measures and consequences
1. Mild Tolerated without medication
2. Moderate Need of medication due to AE
3. Severe Interruption due to AE
4. Death Due to AE
Table 2
Distribution of 7,102 patients in ﬁeld of diagnoses groups according to the
ICD-10 code system (clear diagnosis missing in 40 patients).
Field of diagnoses Total N % of all
Malignancy 2,950 41.8
Neurology 990 14.0
Hematology 681 9.6
Transplantation & donors 576 8.2
Rheumatology 501 7.1
Endocrinology 446 6.3
Organ rejection 278 3.9
Ophthalmology 146 2.1
Gastro intestinal 130 1.8
Muscular disease 112 1.6
Nephrology 81 1.1
Myocardial disease 79 1.1
Dermatology 52 0.7
Infectious disease 40 0.6
Other groups 40 0.6
Table 3
Distribution (numbers) of the severity of adverse events, ﬁrst up to the
third at the same occasion (% in parentheses). In case of multiple adverse
events during an apheresis procedure, the most severe is listed ﬁrst, fol-
lowed by the second most severe and then the third.
Adverse event (AE) First AE Second AE Third AE
Mild 1,154 (2.4) 34 (0.1) 5 (0.0)
Moderate 1,438 (3.0) 81 (0.2) 10 (0.0)
Severe 168 (0.35) 13 (0.0 4 (0.0)
Total AE 2,760 (5.8) 128 (0.3) 19 (0.05)
Table 4
Distribution of all procedures in the most common groups of diagnoses
according to the ICD-10 code, and related to the extent of various grades
of adverse event (AE). Reference is the value achieved for all procedures
(total).
Field of diagnoses % of all
proc.
Mild
AE
Moderate
AE
Severe
AE
Endocrinology 32.0 3.7aaa 1.8bbb 0.2bb
Neurology 17.0 1.9bb 2.2bbb 0.4
Malignancy 14.7 1.1bbb 4.9aaa 0.2
Rheumatology 10.1 2.0 5.3aaa 0.6aa
Hematology 8.0 2.0 3.8aa 0.4
Organ rejection 7.1 0.5bbb 0.8bbb 0.2
Gastro intestinal 2.5 5.7aaa 1.8b 0.3
Transplantation & donors 2.1 2.2 5.3aaa 0.4
Ophthalmology 1.6 2.2 3.9 0.4
Nephrology 1.3 1.5 3.9 1.0a
Total N = 47856 (reference) 100 2.4 3.0 0.3
More than reference: aaap < 0.001; aap < 0.01; ap < 0.05; Less than refer-
ence: bbbp < 0.001; bbp < 0.01; bp < 0.05.
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at a peripheral site or a local hematoma (Table 5). Moder-
ate AEs were mainly experienced as tingling sensations
(Table 6).
3.2. Severe adverse events
The interruption of apheresis due to severe adverse
symptoms was registered in 168 procedures (Table 7).
3.3. Change of AEs over time
The evolution in number and grade of AEs over the years
is illustrated in Fig. 1. The incidence of mild and severe
events decreased over time (mild: r = −0.64, p = 0.036; severe
AEs r = −0.86, p = 0.001, Spearman’s test) while the moder-
ate AEs remained constant.
In general, there was an increased risk for AEs during the
ﬁrst apheresis procedure compared to the subsequent ones
(8.9% vs 6.1%, p < 0.001, RR 1.4, CI 1.3–1.6). When multiple
symptoms appeared during an apheresis procedure, the risk
for severe AEs was increased. Women had a greater risk for
AE than men both during the ﬁrst (p < 0.001, RR 1.4, CI 1.2–
1.7) and the following procedures (p < 0.001, RR 1.5, CI
1.3–1.6).
There was a weak correlation (r < 0.1, p < 0.001) between
the severity of AEs and both the volume processed and the
volume of replacement ﬂuid (not identical with volume
processed).
3.4. Type of procedure
Therapeutic apheresis procedures using ﬁltration had
more AEs then those performed with a centrifugation tech-
nique (11% versus 6%, p-value <0.0001, OR 1.8, CI: 1.5–2.3).
Signiﬁcant differences were valid for mild, moderate and
severe AEs (Table 8). The differences in AE between other
procedures and plasma exchange with centrifugation tech-
nique are given in Table 8. In some groups, only a few
treatments were done, which did not allow statistical
comparison.
3.5. Anticoagulation
Information on anticoagulation together with the pres-
ence or absence of AEs was registered in 44,154 procedures
(Table 9). Comparison of various anticoagulation methods
used indicated that procedures with heparin compared to
those using acid citrate dextrose, solution A (ACD-A, ap-
proximately 2.1% citrate) or solution B (ACD-B, approximately
1.2% citrate) had more mild (RR 1.97, CI 1.70–2.30) and less
moderate (RR 0.30, CI 0.23, −0.40) or less severe AEs (RR 0.47,
CI 0.26–0.88). When the combination of ACD-A and heparin
was used compared to ACD-A or B there were more mod-
erate (RR 1.74, CI 1.52–1.99), but less severe AEs (RR 0.30,
CI 0.22–0.40). Procedures with citrate phosphate dextrose
(CPD) versus ACD-A or ACD-B showed lessmild AEs (RR 0.64,
C 0.46–0.88), but more moderate side effects (RR 1.96, CI
1.67–2.30, Table 9).
3.6. Access
AEs were also analyzed in relation to the access using
‘peripheral vein to peripheral vein’ as the reference
Table 5
Most common ﬁndings of mild speciﬁed AE/10,000 procedures.
Symptom, reason AE/10,000
Access problems 130
Hypotension 36
Tingling 19
Device problems 17
Urticaria 12
Nausea/vomiting 12
Hematoma at puncture site 10
Hypertension 5
Flush 2
Phlebitis 2
Shivering, fever 2
Arrhythmia 1
Back pain 1
Vertigo 1
Table 6
Most common ﬁndings of moderate speciﬁed AEs/10,000 procedures.
Symptom, reason AEs
Tingling 174
Urticaria 45
Hypotension 30
Nausea 9
Technical problems 6
Hypertension 6
Chills and fever 6
Flush 5
Table 7
Severe adverse events (primary reason in 168 procedures) resulting in in-
terruption of apheresis given as speciﬁed AEs/10,000 procedures.
Symptom, reason AEs
Hypotension, syncope 11
Urticaria 6
Fever, chills 3
Nausea, vomit 2
Access problem 2
Flush 2
Tingling, stitching 2
Arrhythmia 2
Bronchospasm 1
Quincke edema 1
Technical problem 0.8
Abdominal pain 0.8
Back pain 0.8
Epilepsy 0.6
Hypertension 0.4
Spasm 0.4
Asystolia 0.2
TRALI chest pain 0.2
Anaphylaxis 0.2
Gastro intestinal bleeding 0.2
Wrong plasma 0.2
Adverse event to drug 0.2
Chest pain 0.2
Anxiety + hyperventilation 0.2
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(Table 10). Procedures performed when a central access was
usedwere related tomore severe AEs. Access problemswere
mainly present when using peripheral veins, but also with
an AV-ﬁstula and AV-graft (Table 11).
3.7. Donor vs. patient apheresis, collection of cells for
cellular therapy
Table 12A includes data of adverse events of those pro-
cedures registered for autologous versus allogeneic collection.
Donor apheresis was performed as cytapheresis for periph-
eral leukocyte and stem cell collections (n = 620 donors,
56% men) in 1,684 occasions. The mean age was 46 years
(±14, range 3–74 years). The grade of adverse events is
shown in Table 12A. There were more mild AEs during
allogenic procedures (p < 0.001, RR 3.2, CI 2.3–4.4), more
moderate AEs during autologous procedures (p = 0.006,
RR 1.4, CI 1.1–1.9), and there was no difference for severe
AEs.
Seventy percent of the mild AEs were due to problems
with access. The various other symptoms are given in
Table 12B.
Fig. 1. Distribution (in %) of mild (open), moderate (hatched) and severe (ﬁlled) adverse events over the observation period from 2004 to 2014.
Table 8
Percentage of adverse events (AE) graded as mild, moderate and severe in 44,856 procedures compared to reference (plasma ex-
change by centrifugation).
Apheresis procedure used Grade of AE Total % of total
apheresis
Mild Moderate Severe N =
PEx, centrifugation (reference) 1.6 3.8 0.7 15,948 36
PEx, ﬁltration 2.9aaa 6.6aaa 1.0a 994 2
Cell collection, allo PBSC 4.3aaa 3.9 0.2 1,652 4
Cell collection, auto PBSC 1.2 6.8aaa 0.1 3,096 7
Leukapheresis, centrifugation 1.8 4.5 0.4bb 1,569 3
Erythrapheresis 1.4 0.4bbb 0.0bbb 1,345 3
LDL-apheresis 4.4aaa 0.4bbb 0.1bb 4,804 11
LDL-apheresis, adsorption 4.0aaa 2.6bbb 0.1bbb 5,834 13
LDL-apheresis, ﬁltration 5.6aa 0.8bbb 0.1 2,063 5
LDL-apheresis, precipitation 8.1aa 0.0 0.0 74 0
LDL-apheresis, other 0.0 0.0 0.0 1 0
Protein A adsorber 4.8aa 2.8 1.1aaa 1,074 2
Cascade ﬁltration 0.3bb 8.9aaa 0.1bbb 757 2
ECP 0.9bb 1.5bbb 0.0a 3,199 7
Leukapheresis, ﬁltr./adsorption 0.5 4.4a 0.0 205 0
Leukapheresis, Nikisso column 6.3 0.0 0.0 16 0
Leukapheresis, Otsuka column 0.0 0.8b 0.0b 242 1
Rheopheresis 5.9aa 2.1 0.3 388 1
Liver detoxiﬁcation 0.0 6.7 0.0 15 0
Lp(a) adsorption 1.5 0.0bb 0.0bb 204 0
IgG adsorption, Sheep ab 3.3aa 1.5bb 0.2bb 614 1
ABO mismatch adsorption 1.2 5.1 0.0 671 1
Adsorption, other 13.0aa 2.2 0.0 46 0
Total 2.6 3.2 0.4 44,856
PEx = plasma exchange; PBSC = peripheral blood stem cell collection; ECP = extra corporeal photopheresis therapy; more than ref-
erence: aaap < 0.001; aap < 0.01; ap < 0.05; less than reference: bbbp < 0.001; bbp < 0.01; bp < 0.05.
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3.8. Colloid replacement ﬂuids
The data of adverse events when using replacements
ﬂuids are shown in Tables 13 and 14A–C. Albumin and
plasma were the main replacement ﬂuids given during a
plasma exchange (PE). For albumin, a 4% solution was most
frequently used (54%) followed by a 5% solution (38%). When
plasma was used as replacement ﬂuid, fresh frozen plasma
wasmost common (FFP; 69%) and then liquid stored plasma
(25%). Cryoprecipiate poor plasma was more rarely used
(4%) as was Octaplas® (2%) and Octaplas LG® (0.2%).
Hydroxyethyl starch (HES) was used in 1.5% of procedures
that were given replacement. When HES was used, it was
as part of the replacement during PE by centrifugation (66%)
Table 9
Distribution of adverse events in relation to anticoagulation used. Statistical comparison was performed with acid
citrate dextrose solution A (ACD-A) or solution B (ACD-B) as reference related to the other options containing more
than 150 procedures.
Mild Moderate Severe Total N
ACD-A or ACD-B (reference) 2.4 3.0 0.4 30,605
Heparin (standard) 4.8aaa 0.9bbb 0.2b 5,572
ACD + heparin 2.1 5.3aaa 0.2b 4,915
CPD. citrate 1.5bb 6.0aaa 0.3 2,659
Low molecular weight heparin (LMWH) 2.9 3.5 0.6 170
Hespan and citrate 0.0 0.0 0.0 57
ACD + LMWH 6.5 2.2 2.2 48
Heparin + ACD-A 4.4 4.4 4.4 45
Macrodex and NaCitrate 0.0 0.0 0.0 37
No anticoagulation 5.6 0.0 0.0 18
Heparin + CPD 0.0 0.0 0.0 3
CPD + heparin 0.0 0.0 0.0 1
Heparin + LMWH 0.0 0.0 0.0 1
Other 0.0 0.0 0.0 23
Total 2.6 3.2 0.4 44,154
More than reference: aaap < 0.001; less than reference: bbbp < 0.001; bbp < 0.01; bp < 0.05.
Table 10
Distribution of accesses in relation to severity of adverse events. Statistical comparison of accesses with more than 200 procedures to peripheral vein to
vein in relation to grade of AE.
Mild Moderate Severe Total N % of total
Peripheral vein to vein (reference) 2.6 3.3 0.2 18,380 64.3
Femoral vein, double lumen 1.0bbb 3.3 0.3aa 2,395 8.4
Jugular vein, double lumen 1.9b 3.8 0.4a 3,132 11.0
Subclavian vein, double lumen 0.9bbb 4.2a 0.4 2,726 9.5
AV ﬁstula 3.1 1.3bbb 0.1 1,112 3.9
AV graft 4.8 2.7 0.0 146 0.5
Artery to artery 0.0 0.0 0.0 5 0.0
Other 0.7 1.3 0.0 153 0.5
Hemoport 0.0 0.0 0.0 109 0.4
Femoral vein to peripheral 2.3 4.5 0.0 44 0.2
Jugular vein to peripheral 0.0 5.1 0.9 117 0.4
Subclavian vein to peripheral 0.0 4.8 0.0 63 0.2
Artery to vein 0.5 7.4aa 0.9 215 0.8
More than reference: aap < 0.01; ap < 0.05; Less than reference: bbbp < 0.001; bp < 0.05.
Table 11
Distribution of 10 most common adverse events (episodes/10,000 procedures) in relation to access (Information from a total of 31,426 procedures).
Peripheral
vein to vein
Femoral
veina
Jugular
veina
Subclavian
veina
AV
ﬁstula
AV
graft
Artery
to vein
Total
AEs N
Tingling 242 203 162 294 30 102 221 697
Access problem 148 36 11 18 148 204 44 346
Hypotension/syncope 58 52 81 36 66 0 0 182
Urticaria 37 40 126 98 22 51 310 171
Technical problems 12 4 37 7 44 51 0 48
Bleeding, hematoma 17 0 0 4 0 102 0 37
Nausea/vomit 9 16 20 11 0 0 44 33
Fever/chills 5 16 11 15 0 0 44 24
Hypertension 4 36 8 4 0 0 44 24
Flush 2 8 17 7 7 0 0 16
a Double lumen catheter for access.
7M. Mörtzell Henriksson et al. / Transfusion and Apheresis Science 54 (2016) 2–15
or ﬁltration (8%) and during cell apheresis (32%). In 26% of
these, HES was the only replacement ﬂuid.
Among the severe AEs, hypotension and syncope were
most common, which was especially noted when albumin
was used as a replacement (48% if albumin only, 6% if
albumin and plasma, 12% if only plasma). In 30% of the pa-
tients with hypotension, neither plasma nor albumin was
used. Urticaria was more often related to the use of plasma
(76%). Compared to apheresis procedures with saline only,
analyses showed that the risk for urticaria was increased
when apheresis was performedwith replacement of plasma
(p < 0.001, RR 89, CI 28.4–278) or albumin during the pro-
cedure (p < 0.01, RR 4.72, CI 1.39–16.02), and also when the
combination of albumin and plasma (p < 0.001, RR 91,CI
29.0–288) was used. When comparing plasma versus
albumin, the risk for urticaria was higher with plasma
(p < 0.001, RR 18.9, CI 11.6–30.7).
Bronchospasm occurred in 11 procedures. Seven of these
were during PE with centrifugation using FFP as replace-
ment in six and Octoplas® in one. In four procedures, no
replacement was used (autologous stem cell collection in
2, extra corporeal photopheresis and protein A adsorption
in one each).
The incidence of AEs did not differ when plasma only was
used compared with the combination of plasma and
albumin. There was no signiﬁcant difference in regard to the
presence of urticaria or bronchospasm between FFP versus
Octaplas®. Arrhythmia or asystolia was present to a similar
extent if plasma (3/6404) or albumin (4/11365) was used.
Comparison between genders revealed that women ex-
perienced more mild (p = 0.03, RR 1.57, CI 1.04–2.38) and
moderate (p < 0.001, RR 2.0, CI 1.51–2.69) AEs than men
when neither albumin nor plasma was used during the
apheresis. Women experienced more moderate AEs than
Table 12
(A) Adverse events (in %) in donor procedures versus patients (leukapheresis procedures); (B) various symptoms of
adverse events in donor apheresis given as AEs/10,000 procedures (AEs/10E4).
(A) None Mild Moderate Severe AE total Total N
Patients (reference) 1.3 5.9 0.2 7.4 4,836
Donors 4.3aaa 3.9bb 0.2 8.4 1,684
(B) Donor apheresis
Grade of AE Symptoms AEs/10E4
Moderate Tingling, stitching 536
Mild Hypotension 67
Mild Tingling, stitching 42
Mild Access hematoma 25
Moderate Nausea/vomiting 25
Moderate Headache 25
Moderate Hypotension 25
Mild Vertigo 17
Severe Fasciculations 17
Mild Hypertension 8
Mild Phlebitis 8
Mild Nausea/vomiting 8
Moderate Flush 8
Moderate Vertigo 8
Moderate Chills/fever 8
Severe Anxiety & hyperventilation 8
Severe Hypotension 8
More than reference: aaap < 0.001; less than reference: bbp < 0.01.
Table 13
Adverse events (%) graded as mild, moderate and severe in relation to main type of albumin, plasma or hydroxyethyl
starch (HES) used as replacement ﬂuid during plasma exchange with centrifugation.
Replacement N Mild Moderate Severe
Other than albumin (reference) 12,134 1.4 4.3 0.6
Albumin 3.5% 484 0.2bbb 2.9b 0.6
Albumin 4% 6,353 1.3 2.7bbb 0.7
Albumin 5% 4,441 2.1aaa 3.6 0.5
Albumin 20%, diluted 379 2.5 1.0bbb 1.5
Other than plasma (reference) 10,287 1.3 1.8 0.5
Liquid stores plasma 1,717 2.4aaa 5.9aaa 1.3aaa
Fresh frozen plasma 4,824 1.3 6.0aaa 0.7a
Cryoprecipitate poor plasma 282 2.8aaa 5.3aaa 0.7
Octaplas® 155 5.2aaa 1.9 1.3
Octaplas LG® 16 0 0 0
Other than HES (reference) 19,671 1.4 3.4 0.6
HES 328 0.0 0.0bb 0.0
More than reference: aaap < 0.001; ap < 0.05; less than reference: bbbp < 0.001; bbp < 0.01; bp < 0.05.
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men when albumin was used as replacement (p < 0.001, RR
1.21, CI 1.25–1.83), but not when used in combination with
plasma or when plasma was the only option. There was no
difference between the various concentrations of albumin
replacement used and AEs between genders. There was no
difference in the use of calcium prophylaxis between the
genders in the various situations given above.
HES was used as replacement ﬂuid in some procedures
and for this, no AEs were registered (Table 13).
3.9. Calcium given intravenously as prophylaxis
Patients who received intravenous calcium as prophy-
laxis (Ca) experiencedmore AEs than those not using calcium
(Table 15). This difference was valid for mild (p = 0.003, RR
1.35, CI 1.11–1.64), moderate (p < 0.001, RR 1.92 CI 1.69–
2.19) or severe AEs (p < 0.001, RR 1.82 CI 1.29–2.57). The
substitution of Ca varied between treatments such as for
PE by centrifugation when initially 24% of the patients re-
ceived Ca (Fig. 2A) versus 8% of those treated by ﬁltration
(Fig. 2B); for some cell collection and immunoadsorption
techniques more than 90% received Ca. In the sub-analysis
a negative outcome for Ca-prophylaxis was valid for ther-
apeutic apheresis with centrifugation and ﬁltration
procedures, while there were no differences for LDL-
apheresis. Analysis of the various symptoms showed that
for mild AEs, Ca prophylaxis had been used more fre-
quently when tingling (p < 0.002, RR 1.8 CI 1.12–2.93), nausea
and vomiting (p < 0.001, RR 6.1 CI 2.4–15.7) or urticaria
(p = 0.006, RR 2.01 CI 1.2–3.5) were reported, while there
were fewer reports of hypotension (p = 0.004, RR 0.35 CI
0.17–0.73). When comparing PE by centrifugation with all
other apheresis procedures tingling was more prominent
for mild and moderate AEs when using Ca with other
procedures than PE by centrifugation (RR > 2.9). Mild hy-
potension was less common for PE by centrifugation when
Ca was used while for moderate and severe hypotension as
AE, there was no difference if Ca-prophylaxis was used or
not.
For moderate AEs there was a negative effect of Ca for
tingling, nausea and vomiting, urticaria and ﬂushing. No dif-
ference was seen for hypotension.
Severe AEs weremore frequently registered when Cawas
used. The signiﬁcant ﬁndings were for chills/fever
(p = 0.0036, RR 6.90 CI 1.87–25.5) and urticaria (p = 0.038,
RR 2.49 CI 1.14–5.46).
In a multivariate analysis using the grade of AE as the
dependent factor there was an increased risk for AE with
plasma, older age, female gender and Ca (p < 0.001 for all
Table 14
(A) Severe AE/10,000 procedures withmain substitution using either plasma
or albumin as replacement for plasma exchange with centrifugation tech-
nique; (B) moderate AE/10,000 procedures with main substitution using
either plasma or albumin as replacement for plasma exchange with cen-
trifugation technique; (C)mild AE/10,000 procedures withmain substitution
using either plasma or albumin as replacement for plasma exchange with
centrifugation technique.
Plasma Albumin
(A) Severe grade AE in %
Urticaria, conjunctivitis 25 12
Chills and fever 16 9
Hypotension, syncope 11 25
Flush 5 1
Bronchospasm 5 2
Tingling, stitching 4 2
Epilepsy 4 0
Quincke edema 4 1
Arrhythmia 3 1
Hypertension 1 0
Asystolia, cardiac arrest 1 1
Phlebitis 1 2
Abdominal pain 1 1
ABO incompatibility 1 0
Access problems 1 2
Technical failure 0 2
(B) Moderate grade AE in %
Urticaria, conjunctivitis 236 69
Tingling, stitching 209 91
Hypotension 32 69
Chills and fever 30 9
Flush 17 9
Hypertension 17 3
Quincke edema 9 2
Nausea and/or vomiting 9 8
Back pain related to apheresis 5 5
Phlebitis 4 3
Abdominal pain 2 4
Vertigo 2 1
Fatigue 2 0
Serum reaction 2 1
Bronchospasm 1 0
Hemolysis (visualized or measured) 1 1
Pruritus 1 0
Palpation 1 0
Epistaxis 1 0
Dyspnea 1 1
Access problems 0 13
Access-hematoma 0 3
Drug related AE 0 1
Myocardial insuﬃciency 0 1
Anaphylactic shock 0 1
Late complication, other 0 1
Access-hematoma, prolonged bleeding 0 1
Technical failure 0 0
(C) Mild grade AE in %
Urticaria, conjunctivitis 65 13
Tingling, stitching 32 27
Access problems 25 33
Technical failure 9 7
Chills and fever 6 4
Access-hematoma 6 13
Late hepatitis C (within 4 months after
apheresis)
6 0
Nausea and/or vomiting 5 7
Flush 5 3
Back pain related to apheresis 5 3
Hypotension 2 46
Bronchospasm 2 0
Vertigo 1 1
Arrhythmia 1 1
Phlebitis 0 2
Hypertension 0 1
Abdominal pain 0 1
Headache 0 1
Access-hematoma, prolonged bleeding
afterwards
0 1
Table 15
Distribution of grade of adverse events (AE) (in %) and use of calcium pro-
phylaxis or No prophylaxis (reference). Data presented for 26,036
procedures.
No prophylaxis Ca-prophylaxis
Non AE % 95.4 92.2
Mild 1.4 1.9aa
Moderate 2.7 5.2aaa
Severe 0.4 0.7aaa
More than reference: aaap < 0.001; aap < 0.01.
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variables) while albumin and center effect were not signif-
icant in the model.
Tables 16–18 lists the most occurring symptoms (ex-
cluding access and technical problems) for frequently used
procedures. Patients treated by leukocytapheresis using
columns or ﬁlters, for e.g., ulcerative colitis, complained of
tingling (moderate grade, 86%) and abdominal pain (mod-
erate grade, 14%). Patients treated with sheep antibody
immunoadsorption complained of nausea or vomiting (mild
grade, 43%), tingling (moderate grade, 26%) and chills/
fever (mild, 13%).
4. Discussion
Data prospectively collectedwithin theWAA registry over
the years show that the incidence of mild and severe AEs
has decreased. The reduction in mild AEs may be due to
various preventive measures. Another reason may be that
centers entering data over time become less prone to reg-
ister mild AEs. However, more than 50% of themild AEs were
due to access problems and among accesses the highest in-
cidence of mild AEs was related to vein to vein access and
to patients that had an arterio-venous ﬁstula or graft.
The reduction in severe AEs over time is probably related
to an increased awareness of side effects and the staff being
more alert to prevent progression into severe AEs.
Previous studies have reported death caused by apheresis
in 0.05% of treatments [33]. Although there was no evident
death due to the apheresis in more than 50,000 proce-
dures in this registry, severe AEs occurred in 4 of 1000
procedures. This included patients with asystole that were
resuscitated and others with severe arrhythmia. Patients at
higher risk for AE are those getting their ﬁrst apheresis treat-
ment procedure. This might be due to the fact that the
patients are less familiar with the ﬁrst treatment, but may
also be due to more awareness of the staff to AEs if the
patient reacted during the ﬁrst procedure. Such aware-
ness can be increased if the patient’s history indicates
tendencies for allergic reactions. An increased risk is also
present, due to activation of the bradykinin system, when
a patient is treated with angiotensin converting enzyme in-
hibitors in combination with apheresis using polysulphone
ﬁlters. The blood membrane interaction thereby is in-
creased [34].
The present study showed that plasma exchange and the
use of liquid stored plasma as replacement ﬂuid could
explain a higher incidence of AE’s. These data conﬁrmed pre-
vious reports [22,35] that side effects were more common
in women than men. Further investigation of liquid plasma,
stored at 2–6 °C for up to 42 days, showed an early (<14 days
of storage) cold-induced contact activation with loss of C1
INH-function. This was observed in plasma from female
donors [36]. The extent of activation of the complement
system was further investigated during prolonged storage
of plasma at 2–6 °C [37]. Different alterations caused by
storage of plasma are diﬃcult to evaluate clinically. Mor-
bidity in terms of AEs may differ [16], but short-term
mortality seems to be unaffected [37]. The increased vul-
nerability in female patients undergoing therapeutic
apheresis remains to be further explored.
As was noted previously [22], PE using ﬁltration tech-
nique resulted in almost double the number of AEs than PE
with centrifugation technique. Although it is known that the
complement system is activated more by ﬁltration proce-
dures [38], it is possible that experience of the center is at
play in this observation. An experienced center that per-
forms many aphereses may buy a centrifuge, whereas a
center that performs apheresis occasionally usesmembranes.
The present study also shows that the extent of AEs also
differs in relation to what type of disease the patient has.
Therefore, most severe AEs were noted for patients suffer-
ing from nephrological and rheumatological diseases and
least for those who were treated for hypercholesterolemia
by LDL apheresis. The data cannot clarify if this is due to
the underlying condition or to various medications such as
the use of angiotensin converting enzyme inhibitors, other
antihypertensives, or hypovolemia due to diuretics. However,
differences in AEs between speciﬁc diagnoses were also pre-
viously reported in a more extended analysis [39]. But
these differences may, to some extent, also be due to the
Fig. 2. (A) Percentage of procedures with (ﬁlled squares) or without (open circles) calcium prophylaxis intravenously during plasma exchange with cen-
trifugation. (B) Percentage of procedures with (ﬁlled squares) or without (open circles) calcium prophylaxis intravenously during plasma exchange with
ﬁltration.
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different types of procedures used for various diagnoses, such
as for patients on LDL apheresis that have a lower risk for
severe AEs than patients on other apheresis procedures.
There was also a difference in the incidence of AEs related
to various anticoagulation methods used. This may be due
to citrate leading to hypocalcemia on one hand and inter-
actions with the heparin molecule on the other hand.
Notably, heparin induced thrombocytopenia was only sus-
pected in one case. Thereby the use of heparin showed less
moderate and severe AEs than ACD-A and B. The use of CPD
indicated more moderate AEs than heparin. Maybe these
differences are due to the citrate load and metabolism or a
secondary change of electrolytes, such as reduced ionized
calcium, magnesium, and potassium, that can be noted
during citrate administration [34,35,40–43]. There may also
be retention of citrate if the load is larger [44], and in those
with kidney failure and hemodialysis, there is increased dif-
fusible calcium to 80% of the total calcium and induced
substantial dialytic loss of calcium as well as a prolonged
half life of citrate [45].
Severe AEs were more frequent with femoral and jugular
than with peripheral vein access. This may be due to a dif-
ference in the diagnoses treated and the type of procedure
performed. Therefore, patients with a need for higher blood
ﬂow (e.g. also on acute hemodialysis) or with a prolonged
treatment series (e.g. more severe condition)maymore often
need a central access. A central access, especially a jugular
vein catheter positionedwithin the right atrium of the heart,
may also inﬂuence the sinus node and cardiac rhythm to a
greater extent due to a higher and more localized concen-
tration and effect of citrate either directly or on the level
of ionized ions.
There were signiﬁcantly more mild, but less moderate
AEs in donors than in patients who performed cell apheresis.
The mild component may be due to the fact that a donor
would be more alert to mild side effects than a patient that
has to be treated for a severe disease, and probably accept
more symptoms before complaining.
During PE replacement, the ﬂuid used was mainly
albumin (4% or 5%) and FFP. The AE panorama varied sig-
niﬁcantly for the different replacement ﬂuids. Hypotension
was a greater risk when using albumin while urticaria was
the predominant AE for plasma replacement.
Mild AEs were mainly due to access problems, such as
a need for replacement of a puncture needle at a periph-
eral site or a local hematoma. Hypotension and tingling were
symptoms that were most frequent in mild AEs. Notably, in
some of these procedures, arrhythmia was detected al-
though no medical measures were necessary.
Moderate AEs weremainly experienced as a tingling sen-
sation. It is not obvious that these symptoms were related
to hypocalcemia since the group who were prescribed
calcium as prophylaxismore often suffered from these symp-
toms. Other reasons for tingling during the apheresis
procedure could be hypomagnesemia and hyperventila-
tion, for example.
Severe AEs were mainly due to hypotension. Since hy-
potension was more common when albumin only was used
as replacement, a reason may be a too low colloid osmotic
pressure and reﬁlling of the intravascular volume. The anal-
yses do not clarify if replacement volumes with albumin
were suﬃcient to correct for this. In general, a replace-
ment ratio of 1:1 with a 5% albumin solution should
compensate for colloid osmotic pressure drop. But, pa-
tients with e.g., a neurological disease, may have a reduced
ability for compensatory vasoconstriction. In 30% of the pa-
tients with hypotension, neither plasma nor albumin was
used. A plausible explanation would be that even if the ﬂuid
chosen is adequate in its colloid osmotic concentration, it
is important to reﬁll the volume to at least a 1:1 extent, and
Table 16
Main symptoms (AEs/10,000 procedures) that may be expected to appear
with plasma exchange procedures.
Grade of AE Symptoms AEs
Plasma exchange, centrifugation
Moderate Tingling 99
Moderate Urticaria, conjunctivitis 68
Moderate Chills, fever 42
Mild Chills, fever 10
Mild Urticaria, conjunctivitis 8
Mild Tingling 8
Moderate Chills, fever 8
Moderate Hypertension 8
Moderate Flush 8
Moderate Nausea/vomiting 4
Moderate Back pain 4
Moderate Quincke edema 4
Severe Chills, fever 3
Mild Access hematoma 3
Mild Nausea/vomiting 2
Mild Flush 2
Mild Chills, fever 2
Severe Urticaria, conjunctivitis 1
Severe Chills, fever 1
Severe Tingling 1
Severe Flush 1
Moderate Phlebitis <1
Moderate Abdominal pain <1
Moderate Access hematoma <1
Severe Bronchospasm <1
Mild Back pain <1
Severe Epilepsy <1
Severe Arrhythmia <1
Severe Quincke edema <1
Mild Hypertension <1
Plasma exchange, ﬁltration
Moderate Urticaria, conjunctivitis 305
Moderate Flush 46
Moderate Chills, fever 33
Mild Urticaria, conjunctivitis 29
Moderate Nausea/vomiting 20
Mild Late hepatitis C 15
Moderate Hypertension 13
Mild Tingling 9
Moderate Hemolysis 7
Moderate Arrhythmia 7
Moderate Back pain 7
Moderate Abdominal pain 7
Mild Chills, fever 6
Severe Chills, fever 3
Mild Hemolysis 3
Mild Arrhythmia 3
Mild Back pain 3
Mild Access hematoma 3
Severe Urticaria, conjunctivitis 3
Severe Hypertension 1
Severe Back pain 1
Severe Nausea/vomiting 1
Severe Flush 1
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also adjust the replacement timely with the removal. Oth-
erwise, the reﬁlling volumes may be too small and given
too late to prevent hypotension.
The secondmost frequent severe AEwas urticaria. Plasma
as replacement ﬂuid was more often related to episodes of
urticaria. Arrhythmia was rare and there was no evident dif-
ference in risk to suffer from arrhythmia if plasma or albumin
was used as replacement ﬂuid. Bronchospasm appeared also
in other apheresis procedures (not using colloids as re-
placement ﬂuid) than plasma exchange. In the latter, all of
them had received plasma as replacement.
Calcium/magnesium prophylaxis has been shown to
reduce the extent of adverse events in previous reports
[33–35,42,46,47]. However, the number of procedures in
those reported studies were limited, and in some of them,
the grading of the AE was vague.
Our present data show that procedures performed when
calcium was given intravenously as prophylaxis resulted in
more AEs for all grades. In a sub-analysis the negative
outcome for calcium prophylaxis was valid for therapeu-
tic apheresis with centrifugation and ﬁltration procedures,
while there were no differences for LDL-apheresis.
When analyzing the various symptoms, for mild, mod-
erate and severe AEs, a negative relation with calcium
prophylaxis was even valid for the least expected symp-
toms such as tingling, nausea, vomiting and urticaria.
However, we cannot discriminate if, in some procedures, the
calcium administration was given as treatment due to side
effects, but registered as prophylaxis. One beneﬁcial effect
of calcium prophylaxis may be the ﬁnding of fewer epi-
sodes of mild hypotension while moderate hypotension did
not differ between the groups with or without calcium pro-
phylaxis. Since comparison was made with those not
receiving any calcium at all, the reason could not be due to
a too low dose and thereby lack of general effect. A longi-
tudinal investigation showed that there was only a limited
tendency to increase the use of calcium prophylaxis over
the number of procedures.
The negative effect of calcium prophylaxis seen for chills/
fever and urticaria may be due to an effect of calcium
activating the acute phase reacting systems, including the
complement and the clotting system. An increased tenden-
cy of clotting in the venous bubble trap has been notedwhen
calcium was infused there (personal communication). This
is also in agreement with the physiological function of the
calcium ion.
In a multivariance analysis using the grade of AE as the
dependent factor, there was an increased risk for AE by being
older, being female, using plasma as replacement and with
I.V. calcium as prophylaxis.
Whether the negative effect of calcium as prophylaxis is
due to negative selection of patients that aremore prone to
side effects is not clariﬁed in this study. However, in general,
the use of calcium prophylaxis seemed to be more a habit
of the center and related to the treatment procedure than
a selective effect. The data entered in this study do not dis-
criminate between continuous or intermittent infusion of
calcium. There might be a better preventive effect using a
continuous infusion according to a previous report byWein-
stein [40]. Notable is that the number of treatments in their
study was limited. Although they saw no beneﬁt to oral
supplementation [40], such beneﬁtwas found by Sassi et al.
[48]. In another study, calcium chloride was more effective
than calciumgluconate inmaintaining calcium levels [35,49].
In those studies, the symptoms of paraesthesia were sig-
niﬁcantly reduced by calcium. In addition, the infusion of
citrate during apheresis procedures may result in a prolon-
gation of the QT-time and thereby increased risk for
Table 17
Main symptoms (AEs/10,000 procedures) that may be expected to appear with cellapheresis and LDL-apheresis procedures.
Cellapheresis LDL-apheresis
Grade of AE Symptoms AEs Grade Symptoms AEs
Moderate Tingling 343 Mild Chills, fever 108
Moderate Nausea/vomiting 23 Moderate Tingling 59
Mild Tingling 9 Mild Access hematoma 26
Moderate Chills, fever 9 Moderate Chills, fever 13
Moderate Drug AE 5 Mild Hypertension 13
Mild Nausea/vomiting 4 Mild Nausea/vomiting 9
Mild Vertigo 1 Mild Abdominal pain 4
Mild Chills, fever 1 Mild Phlebitis 4
Mild Arrhythmia 1 Mild Flush 4
Mild Access hematoma 1 Mild Tingling 4
Moderate Hypertension <5 Mild Back pain 4
Moderate Back pain <5 Mild Vertigo 4
Moderate Allergic reaction, other <5 Mild Allergic reaction, other 4
Moderate Tachycardia <5 Mild Hemolysis 4
Moderate Chills, fever <5 Moderate Abdominal pain 3
Moderate Bronchospasm <5 Moderate Hypertension 1
Severe Tingling <1 Mild Headache <4
Severe Chills, fever <1 Severe Back pain <1
Severe Anxiety, hyperventilation <1 Severe Abdominal pain <1
Severe Arrhythmia <1 Moderate Nausea/vomiting <1
Severe Urticaria, conjunctivitis <1 Severe Nausea/vomiting <1
Severe Bronchospasm <1 Severe Chills, fever <1
Mild Angina pectoris <1 Moderate Chills, fever <1
Mild Fatigue <1 Moderate Angina pectoris <1
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arrhythmia [50]. This risk may be greater if the patient has
a central dialysis catheter and if calcium is given intermit-
tently. The change in other electrolytes such asmagnesium
and potassium may further interfere in this regard.
However, to more speciﬁcally clarify the beneﬁts versus
possible disadvantages of substitution of calcium further in-
vestigations should be performed. Those studies should also
consider other ions and the combination of citrate infused
as anticoagulant for the procedure in combination with the
amount of additives present in albumin and plasma prod-
ucts replaced with during treatment. The calcium binding
effect of albumin as replacement must also be considered,
and this effect may also change depending on alterations
by effects such as uremia [51].
Although severe AEs are less frequent, they can appear
evenwith techniques and replacement ﬂuids that would nor-
mally not be related to such procedures. We therefore
suggest the use of regular pulse and blood pressure mea-
surements and careful surveillance, preferably including
cardiac monitoring, during apheresis treatment and having
emergency equipment nearby.
In conclusion, data from the WAA registry indicate that
the diagnosis and treatment procedures as well as the re-
placement ﬂuid seem to participate in the extent and
severity of AEs. Although severe AEs are rare, episodes of
especially severe hypotension, bronchospasm, arrhythmia
and asystole may be critical for the patient. Further studies
must clarify eventual beneﬁts or risks with citrate antico-
agulation and calcium prophylaxis by infusion.
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Overview of page for variables entered into the regis-
try during each procedure.
Table 18
Main symptoms (AEs/10,000 procedures) that may be expected to appear
with immunoadsorption, extracorporeal photopheresis and apheresis in
conjunction with AB incompatible donor transplantation procedures.
Grade of AE Symptoms AEs
Immunoadsorption, protein A
Mild Hypertension 66
Moderate Tingling 36
Mild Tingling 33
Mild Phlebitis 16
Mild Nausea/vomiting 16
Moderate Pruritis, generalized 14
Moderate Urticaria, conjunctivitis 14
Moderate Nausea/vomiting 9
Moderate Hypoglycemia 9
Mild Flush 8
Mild Vertigo 8
Mild Chills, fever 8
Mild Access hematoma 8
Moderate Hypertension 5
Moderate Angina pectoris 5
Moderate Flush 5
Moderate Chills, fever 5
Severe Nausea/vomiting 4
Severe Arrhythmia 2
Severe Flush 2
Severe Chills, fever 2
Severe Quincke edema 2
Severe Anaphylaxis 2
Severe Bronchospasm 2
Extracorporeal photopheresis
Moderate Tingling 114
Mild Tingling 4
Mild Chills, fever 4
Moderate Chills, fever 2
Mild Arrhythmia 1
Mild Phlebitis 1
Mild Chills, fever 1
Mild Bronchospasm 1
Mild Access hematoma 1
Severe Intestinal bleeding <1
A/B-immunoadsorption
Moderate Urticaria, conjunctivitis 207
Moderate Pruritis, generalized 91
Moderate Tingling 45
Moderate Hypertension 45
Moderate Nausea/vomiting 30
Moderate Abdominal pain 15
Moderate Flush 15
Moderate Chills, fever 15
Mild Tingling 4
Mild Chills, fever 4
Mild Urticaria, conjunctivitis 4
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